Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe

• Published in: Journal of the European Academy of Dermatology and Venereology Vol. 29; no. 12; pp. 2342 - 2348
• Main Authors: Lacour, J-P., Ulrich, C., Gilaberte, Y., Von Felbert, V., Basset-Seguin, N., Dreno, B., Girard, C., Redondo, P., Serra-Guillen, C., Synnerstad, I., Tarstedt, M., Tsianakas, A., Venema, A.W., Kelleners-Smeets, N., Adamski, H., Perez-Garcia, B., Gerritsen, M.J., Leclerc, S., Kerrouche, N., Szeimies, R-M.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.12.2015; Wiley
• Subjects: Aged; Aged, 80 and over; Aminolevulinic Acid - adverse effects; Aminolevulinic Acid - analogs & derivatives; Aminolevulinic Acid - therapeutic use; Europe; Facial Dermatoses - drug therapy; Female; Human health and pathology; Humans; Keratosis, Actinic - drug therapy; Life Sciences; Male; Middle Aged; Pain - etiology; Patient Satisfaction; Photochemotherapy - adverse effects; Photochemotherapy - methods; Photosensitizing Agents - adverse effects; Photosensitizing Agents - therapeutic use; Scalp Dermatoses - drug therapy; Severity of Illness Index; Single-Blind Method; Skin Cream; Sunlight - adverse effects; Treatment Outcome
• ISSN: 0926-9959; 1468-3083; 1468-3083
• DOI: 10.1111/jdv.13228

Background Unmet needs exist in actinic keratosis (AK) treatment. Daylight photodynamic therapy (DL‐PDT) has shown good efficacy and safety results compared to conventional PDT (c‐PDT) in a recent Phase III multi‐centre randomised controlled trial in Australia among 100 subjects with AKs. Objectives...